NOTCH1 and acute lymphoblastic leukemia: Despite the initial lukewarm results of GSI clinical trials in T-ALL, NOTCH1 remains one of the most desirable targets in this disease, and several efforts are on-going to improve selectivity (NOTCH1 versus NOTCH2-4) [41] and reduce off-target effects (mutated NOTCH1 versus wild type) [42].